
Investments
516Portfolio Exits
56Funds
10SMBC Venture Capital Web Traffic
SMBC Venture Capital Rank
Research containing SMBC Venture Capital
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned SMBC Venture Capital in 1 CB Insights research brief, most recently on Nov 4, 2019.
Latest SMBC Venture Capital News
Jan 7, 2022
January 06, 2022 07:00 PM Eastern Standard Time TOKYO--( BUSINESS WIRE )-- Cellusion Inc. , a regenerative medicine startup aiming to solve the global Corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells (CECSi Cells) for bullous keratopathy novel treatment (PJ code: CLS001), today announced it has completed a 1.1 billion yen fundraising round led by existing investors DBJ Capital, Keio Innovation Initiative, and SMBC Venture Capital and new investors Gemseki, Toho Holding, Toyo Seikan Group Holdings and University of Tokyo Edge Capital Partners. The new round brings Cellusion’s total funding in the past year to 1.7 billion yen. [Use of the Funding] Cellusion will use the funding to prepare for the company-sponsored phase 1/2 clinical trials of CLS001 in Japan and overseas, enlarge both of its Tokyo-based research and business teams, and proceed with R&D activities of other pipelines. In addition, by promoting business cooperation with Toho Holdings, Japan-based pharmaceutical wholesaler, and Toyo Seikan Group Holdings, a Japanese multinational conglomerate packaging materials manufacturer, to build the supply chain of CLS001. Cellusion will enhance its efforts to deliver CLS001 for bullous keratopathy patients all over the world. [About CLS001] In spite of the fact that more than 13 million waiting patients for potential blinding diseases such as Bullous Keratopathy, which can only be prevented by corneal transplantation, only about 180,000 corneal transplants are performed annually worldwide. The reason for such a large medical supply-demand gap generated is because current treatments require donor corneas, skilled corneal transplant ophthalmologists, and Eye Banks. Cellusion is developing CLS001, CECSi cells for Corneal Endothelial regeneration to cure Bullous Keratopathy which is applied more than half of all cases of corneal transplantation. CLS001 is expected to replace the current supply limitations by combining “CECSi Cells made from iPS cells with excellent proliferative properties” and "a simple injection cell delivery procedure without needs of human expertise.“ The initiation approval of the CLS001 first in human investigator-initiated clinical study has already been obtained from the Keio University Specially Certified Committee for Regenerative Medicine as well as the Health Sciences Council of MHLW, the Ministry of Health, Labor and Welfare of Japan in July 2021. Keio University and Cellusion are scheduled to start the study at Keio University Hospital as soon as it is ready. [About Cellusion Inc.] Cellusion is a regenerative medicine startup born from the Department of Ophthalmology, Keio University School of Medicine in 2015. Cellusion aims to contribute to the improvement of health and well-being around the world by solving unmet medical needs in medicine with its cutting-edge cell therapy technologies, including a unique differentiation induction method from iPS cells to CECSi Cells. Cellusion’s mission is to a community the clear vision of the future with cellular technology breakthrough. Company: Cellusion Inc.
SMBC Venture Capital Investments
516 Investments
SMBC Venture Capital has made 516 investments. Their latest investment was in Mov as part of their Series A on May 5, 2022.
SMBC Venture Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
5/24/2022 | Series A | Mov | $5.53M | No | 2 | |
5/23/2022 | Series B | DoctorMate | $7.84M | Yes | 1 | |
5/12/2022 | Seed VC | Definer | $0.51M | Yes | 1 | |
4/26/2022 | Series A | |||||
4/21/2022 | Seed VC - II |
Date | 5/24/2022 | 5/23/2022 | 5/12/2022 | 4/26/2022 | 4/21/2022 |
---|---|---|---|---|---|
Round | Series A | Series B | Seed VC | Series A | Seed VC - II |
Company | Mov | DoctorMate | Definer | ||
Amount | $5.53M | $7.84M | $0.51M | ||
New? | No | Yes | Yes | ||
Co-Investors | |||||
Sources | 2 | 1 | 1 |
SMBC Venture Capital Portfolio Exits
56 Portfolio Exits
SMBC Venture Capital has 56 portfolio exits. Their latest portfolio exit was GROOVE X on March 15, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
3/15/2022 | Acquired | 1 | |||
3/14/2022 | Acquired | 1 | |||
3/1/2022 | Acquired | 2 | |||
SMBC Venture Capital Acquisitions
1 Acquisition
SMBC Venture Capital acquired 1 company. Their latest acquisition was Collabos on June 30, 2011.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
6/30/2011 | Other | Management Buyout | 1 |
Date | 6/30/2011 |
---|---|
Investment Stage | Other |
Companies | |
Valuation | |
Total Funding | |
Note | Management Buyout |
Sources | 1 |
SMBC Venture Capital Fund History
10 Fund Histories
SMBC Venture Capital has 10 funds, including Next Generation Corporate Growth Support I.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
3/29/2017 | Next Generation Corporate Growth Support I | Early-Stage Venture Capital | Open | $8.72M | 1 |
12/31/2016 | SMBC VC 3 | Early-Stage Venture Capital | Closed | 1 | |
12/31/2014 | SMBC VC 2 | Early-Stage Venture Capital | Closed | 1 | |
6/6/2012 | SMBC Business Development II | ||||
7/22/2011 | SMBC VC 1 |
Closing Date | 3/29/2017 | 12/31/2016 | 12/31/2014 | 6/6/2012 | 7/22/2011 |
---|---|---|---|---|---|
Fund | Next Generation Corporate Growth Support I | SMBC VC 3 | SMBC VC 2 | SMBC Business Development II | SMBC VC 1 |
Fund Type | Early-Stage Venture Capital | Early-Stage Venture Capital | Early-Stage Venture Capital | ||
Status | Open | Closed | Closed | ||
Amount | $8.72M | ||||
Sources | 1 | 1 | 1 |
SMBC Venture Capital Team
3 Team Members
SMBC Venture Capital has 3 team members, including current Chief Executive Officer, President, Kohei Katsukawa.
Name | Work History | Title | Status |
---|---|---|---|
Kohei Katsukawa | Chief Executive Officer, President | Current | |
Daiji Furuta | Managing Director | Current | |
Masahiro Yamaguchi | Managing Director | Current |
Name | Kohei Katsukawa | Daiji Furuta | Masahiro Yamaguchi |
---|---|---|---|
Work History | |||
Title | Chief Executive Officer, President | Managing Director | Managing Director |
Status | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.